Everolimus Export Market Intelligence: India's 87 Suppliers Shipping to 67 Countries — TransData Nexus 2026

Q: Who are the top everolimus exporters from India?

The top everolimus exporters from India are: 1. NATCO PHARMA LIMITED — $20.0M (52.8% market share); 2. ALKEM LABORATORIES LIMITED — $13.2M (34.8% market share); 3. BIOCON PHARMA LIMITED — $1.8M (4.7% market share); 4. BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED — $835.7K (2.2% market share); 5. AEON FORMULATIONS PRIVATE LIMITED — $529.7K (1.4% market share). Together they account for 95.9% of India's total everolimus export value.

Q: What is the total export value of everolimus from India?

The total export value of everolimus from India is $37.9M USD, recorded across 620 shipment transactions from 87 active exporters to 67 destination countries. The average shipment value is $61.1K.

Q: Which countries import everolimus from India?

India exports everolimus to 67 countries worldwide. The top importing countries are: UNITED STATES (50.5% share, $19.1M), GERMANY (15.7% share, $6.0M), MALTA (10.4% share, $3.9M), BRAZIL (8.3% share, $3.1M), SAUDI ARABIA (6.8% share, $2.6M). These five markets account for 91.7% of total export value.

Q: What is the HS code for everolimus exports from India?

The primary HS code for everolimus exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of everolimus exports from India?

The average unit price for everolimus exports from India is $82.98 USD per unit, with prices ranging from $0.01 to $26549.03 depending on formulation, packaging, and order volume. The total market is valued at $37.9M across 620 shipments.

Q: Which ports handle everolimus exports from India?

The primary ports for everolimus exports from India are SAHAR AIR CARGO ACC (INBOM4) (14.7% of shipments), HYDERABAD AIR (14.7% of shipments), SAHAR AIR (12.7% of shipments), HYDERABAD ACC (INHYD4) (9.8% of shipments), DELHI AIR (6.9% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of everolimus?

India is one of the world's leading exporters of everolimus due to its large base of 87 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports everolimus to 67 countries, demonstrating 34% global market coverage.

Q: What certifications do Indian everolimus exporters need?

Indian everolimus exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import everolimus from India?

There are 135 registered buyers importing everolimus from India, spread across 67 countries. The repeat buyer rate is 57.0%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top everolimus supplier from India?

NATCO PHARMA LIMITED is the leading everolimus exporter from India with a market share of 52.8% and total export value of $20.0M across 223 shipments. The top 5 suppliers together control 95.9% of total export value.

Suresh Sormare

Everolimus

India Pharmaceutical Trade Intelligence

$37.9M87 Suppliers67 CountriesHS 30049049

ExportsIndia → UNITED STATES50.5%India → GERMANY15.7%

ImportsSWITZERLAND → India$2.8M UNITED STATES → India$346.7K

#1 Supplier: NATCO PHARMA #1 Buyer: ASCEND GMBH

Everolimus Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Everolimus to the World

Between 2022 and 2026, India exported $37.9M worth of everolimus across 620 verified shipments to 67 countries — covering 34% of world markets in the Immunosuppressants segment. The largest destination is UNITED STATES (50.5%). NATCO PHARMA LIMITED leads with a 52.8% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Everolimus export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Everolimus export data snapshot — $37.9M · 87 exporters · 67 countriesTransData Nexus · Indian Customs Data

Top Everolimus Exporters from India

87 active exporters · Ranked by export value

View all 87 →

Top Everolimus Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	NATCO PHARMA LIMITED	$20.0M	223	8	52.8%
2	ALKEM LABORATORIES LIMITED

Top Countries Importing Everolimus from India

67 destination markets · Ranked by import value

All 67 countries →

Top Countries Importing Everolimus from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	UNITED STATES	$19.1M	50.5%
2	GERMANY	$6.0M	15.7%
3	MALTA	$3.9M	10.4%
4	BRAZIL	$3.1M	8.3%
5	SAUDI ARABIA	$2.6M	6.8%
6	SRI LANKA	$563.7K	1.5%
7	FRANCE	$548.8K	1.4%
8	VENEZUELA	$460.3K	1.2%
9	PERU	$440.1K	1.2%
10	MALAYSIA	$425.5K	1.1%

UNITED STATES is India's largest everolimus export destination, absorbing 50.5% of total exports worth $19.1M. The top 5 importing countries — UNITED STATES, GERMANY, MALTA, BRAZIL, SAUDI ARABIA — together account for 91.7% of India's total everolimus export value. The remaining 62 destination countries collectively receive the other 8.3%, indicating a broadly diversified export footprint across multiple regions.

Who Supplies Everolimus to India?

13 origin countries · Total import value: $3.7M

India imports everolimus from 13 countries with a combined import value of $3.7M. The largest supplier is SWITZERLAND ($2.8M, 43 shipments), followed by UNITED STATES and UNITED KINGDOM. All values are from Indian Customs (DGFT) import records.

Countries Supplying Everolimus to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	SWITZERLAND	$2.8M	43	75.8%
2	UNITED STATES	$346.7K	40	9.5%
3	UNITED KINGDOM	$186.0K	9	5.1%
4	GERMANY	$162.3K	16	4.4%
5	TAIWAN	$139.0K	5	3.8%
6	CHINA	$23.0K	2	0.6%
7	ROMANIA	$20.4K	2	0.6%
8	NETHERLANDS	$7.2K	1	0.2%
9	SINGAPORE	$1.4K	3	0.0%
10	CANADA	$627	1	0.0%

Showing top 10 of 13 origin countries

SWITZERLAND is the largest supplier of everolimus to India, accounting for 75.8% of total import value. The top 5 origin countries — SWITZERLAND, UNITED STATES, UNITED KINGDOM, GERMANY, TAIWAN — together supply 98.6% of India's everolimus imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Everolimus

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, everolimus is marketed under the brand name Afinitor, with initial FDA approval granted to Novartis Pharmaceuticals Corporation on March 30, 2009, for the treatment of advanced renal cell carcinoma. Subsequent approvals expanded its indications to include progressive neuroendocrine tumors of pancreatic origin (May 5, 2011) and progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin (February 26, 2016).

The FDA has approved generic versions of Afinitor; however, the availability of these generics in the market can be influenced by existing patents or exclusivity rights. As of March 2026, there are no active FDA import alerts specifically targeting everolimus, indicating compliance with U.S. regulatory standards.

The substantial export volume of everolimus from India to the U.S., accounting for 50.5% of total exports, underscores the importance of Indian manufacturers in the U.S. pharmaceutical supply chain. The presence of 87 active Indian exporters reflects a competitive landscape, necessitating strict adherence to FDA regulations to maintain market access.

2EU & UK Regulatory Framework

In the European Union, everolimus is authorized under the brand name Afinitor, with the European Medicines Agency (EMA) granting marketing authorization on August 3, 2009, for the treatment of advanced renal cell carcinoma. The authorization has since been extended to include other indications, such as certain types of breast cancer and neuroendocrine tumors. (ema.europa.eu)

The United Kingdom, following its departure from the EU, continues to recognize EMA approvals through the Medicines and Healthcare products Regulatory Agency (MHRA). Manufacturers exporting everolimus to these markets must comply with EU Good Manufacturing Practice (GMP) standards, ensuring product quality and safety.

3WHO Essential Medicines & Global Standards

Everolimus is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, highlighting its significance in treating priority health conditions. (who.int) Compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is essential for manufacturers to ensure global acceptance and quality assurance of everolimus products.

4India Regulatory Classification

In India, everolimus is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for everolimus, allowing market-driven pricing. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international trade.

5Patent & Exclusivity Status

The primary patents for everolimus have expired, leading to increased generic competition. This has resulted in a more competitive market landscape, with multiple manufacturers producing and exporting the drug. The presence of 87 active Indian exporters reflects this competitive environment, emphasizing the need for stringent quality control and regulatory compliance to maintain market share.

6Recent Industry Developments

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines updated the Model List to its 24th edition, reaffirming the inclusion of everolimus for specific indications. (who.int)

In September 2025, the WHO launched a digital version of its Model List of Essential Medicines, enhancing accessibility and facilitating the integration of essential medicines like everolimus into national healthcare systems. (who.int)

These developments underscore the global recognition of everolimus's therapeutic value and the ongoing efforts to ensure its availability and proper use in healthcare systems worldwide.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Supply Chain Risk Assessment — Everolimus

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, including the production of Everolimus, heavily relies on Key Starting Materials (KSMs) sourced from China. Approximately 70–80% of global KSM supply is controlled by China, making it a dominant player in this sector. This dependency poses significant risks, as any disruption in Chinese supply chains can directly impact Indian API manufacturing. For instance, in 2025, environmental regulations led to the shutdown of numerous Chinese factories, causing a surge in KSM prices and subsequent challenges for Indian pharmaceutical companies.

The Indian government has initiated measures like the Production Linked Incentive (PLI) scheme to bolster domestic production of APIs and KSMs, aiming to reduce reliance on imports. However, as of November 2024, while two greenfield plants were inaugurated under this scheme to manufacture critical molecules, the overall impact on reducing import dependence remains to be fully realized.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates a high supplier concentration in Everolimus exports from India, with the top five exporters accounting for 95.9% of the market. Notably, NATCO PHARMA LIMITED alone holds a 52.8% share. Such concentration heightens the risk of supply disruptions, as any operational or regulatory issues affecting these key players could significantly impact global supply chains.

Access Complete Everolimus Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 620 transactions across 67 markets.

Request Demo View Pricing

Frequently Asked Questions — Everolimus Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top everolimus exporters from India?

The leading everolimus exporters from India are NATCO PHARMA LIMITED, ALKEM LABORATORIES LIMITED, BIOCON PHARMA LIMITED, and 7 others. NATCO PHARMA LIMITED leads with 52.8% market share ($20.0M). The top 5 suppliers together control 95.9% of total export value.

What is the total export value of everolimus from India?

The total export value of everolimus from India is $37.9M, recorded across 620 shipments from 87 active exporters to 67 countries. The average shipment value is $61.1K.

Which countries import everolimus from India?

India exports everolimus to 67 countries. The top importing countries are UNITED STATES (50.5%), GERMANY (15.7%), MALTA (10.4%), BRAZIL (8.3%), SAUDI ARABIA (6.8%), which together account for 91.7% of total export value.

What is the HS code for everolimus exports from India?

The primary HS code for everolimus exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Everolimus

Everolimus

How India Exports Everolimus to the World

Top Everolimus Exporters from India

Top Countries Importing Everolimus from India

Who Supplies Everolimus to India?

Quick Facts

Related Immunosuppressants

Related Analysis

Need Details?

Regulatory Landscape — Everolimus

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Supply Chain Risk Assessment — Everolimus

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Everolimus Trade Intelligence

Frequently Asked Questions — Everolimus Exports from India

Who are the top everolimus exporters from India?

What is the total export value of everolimus from India?

Which countries import everolimus from India?

What is the HS code for everolimus exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of everolimus exports from India?

Which ports handle everolimus exports from India?

Why is India a leading exporter of everolimus?

What certifications do Indian everolimus exporters need?

How many buyers import everolimus from India?

What is the market share of the top everolimus exporter from India?

Analysis Methodology